Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Eaton Corporation plc (ETN) Price & Performance

Crispr Therapeutics AGTrade
Eaton Corporation plcTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Eaton Corporation plc — how do they compare? Crispr Therapeutics AG trades at $53.65 (market cap $4.88B), while Eaton Corporation plc trades at $430.11 (market cap $164.88B). The key difference: Eaton Corporation plc is far larger — about 33.8× Crispr Therapeutics AG's market cap, and Eaton Corporation plc pays a 1.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Eaton Corporation plc for 31 Days on average.

CRSPETN
Market Cap
$4.88B$164.88B
Volume
2,861,7472,535,086
Sector
HealthIndustrials
52-Week High
$74.92$459.96
52-Week Low
$44.34$315.82
Typical Hold Time
77 Days31 Days
Enterprise Value
$3.30B$185.51B
Dividend Yield
—1.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.

The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.

Eaton Corporation plc

Eaton Corporation (ETN) trades at $424.64, down 1.55% today, with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. ETN maintains robust profitability with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Recent news highlights growing investor attention and positive analyst coverage.

ETN presents a compelling growth story driven by data center demand and grid modernization, with 70% analyst buy ratings and a $502.38 consensus price target suggesting 18% upside. However, elevated valuation multiples (P/E 43.23) and bearish technical indicators warrant caution. Key risks include execution of acquisition strategy and competitive pressures in the electronics manufacturing sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSP
23% Buy77% Sell
Avg holding period · 77 Days
ETN
100% Buy0% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP →

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN →